Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

Journal of Clinical Oncology

Volumn 31, Issue 26, 2013, Pages 3205-3211

  Ascierto, Paolo A ^a   Minor, David ^b   Ribas, Antoni ^c   Lebbe, Celeste ^h   O'Hagan, Anne ^e   Arya, Niki ^e   Guckert, Mary ^e   Schadendorf, Dirk ^j   Kefford, Richard F ^l   Grob, Jean Jacques ⁱ   Hamid, Omid ^d   Amaravadi, Ravi ^f   Simeone, Ester ^a   Wilhelm, Tabea ^k   Kim, Kevin B ^g   Long, Georgina V ^l   Martin, Anne Marie ^e   Mazumdar, Jolly ^e   Goodman, Vicki L ^e   Trefzer, Uwe ^k  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b California Pacific Center for Melanoma Research and Treatment   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Angeles Clinic and Research Institute   (United States)

^e GLAXOSMITHKLINE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ AIX MARSEILLE UNIVERSITY   (France)

^j UNIVERSITY HOSPITAL ESSEN   (Germany)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^l UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; DACARBAZINE; TEMOZOLOMIDE; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; OXIME;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHILL; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GENE MUTATION; HEADACHE; HUMAN; HYPERKERATOSIS; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MULTICENTER STUDY; NAUSEA; NONCARDIAC CHEST PAIN; OVERALL SURVIVAL; PATIENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SKIN CARCINOMA; SKIN PAPILLOMA; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; VERY ELDERLY; VOMITING; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CLINICAL TRIAL; FOLLOW UP; GENETICS; INTERNATIONAL COOPERATION; MELANOMA; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; INTERNATIONAL AGENCIES; MALE; MELANOMA; MIDDLE AGED; MUTATION; OXIMES; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SURVIVAL RATE; YOUNG ADULT;

EID: 84891648456     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.8691     Document Type: Article

References (23)

1. Haluska FG, Tsao H, Wu H, et al: Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 12:2301s-2307s, 2006
2. Long GV, Menzies AM, Nagrial AM, et al: Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29:1239-1246, 2011
3. Wellcome Trust Sanger Institute: Catalogue of Somatic Mutations in Cancer (COSMIC) website. http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/
4. Sosman JA, Kim KB, Schuchter L, et al: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714, 2012
5. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
6. Laquerre S, Arnone M, Moss K: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RafV600E mutation. Mol Cancer Ther 8:B88, 2009 (suppl 12)
7. Ascierto P, Gentilcore G, Madonna G, et al: Are GSK2118436 and GSK112212 effective in melanoma cell lines harboring V600BRAF mutations different from the common V600EBRAF variant? Eur J Cancer 47:S11, 2011 (suppl 4; abstr)
8. Falchook GS, Long GV, Kurzrock R, et al: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 379:1893-1901, 2012
9. Diehl F, Schmidt K, Durkee KH, et al: Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterol 135:489-498, 2008
10. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
11. Chapman PB, Einhorn LH, Meyers ML, et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745-2751, 1999
12. Patel PM, Suciu S, Mortier L, et al: Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). Eur J Cancer 47:1476-1483, 2011
13. Hauschild A, Grob JJ, Demidov LV, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365, 2012
14. Reference deleted
15. Menzies AM, Haydu LE, Visintin L, et al: Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 18:3242-3249, 2012
16. McArthur GA, Shieh F, Hauschild A, et al: Efficacy of vemurafenib in BRAFV600K mutationpositive melanoma disease: Results from the phase 3 clinical study BRIM-3. Pigment Cell Melanoma Res 25:871, 2012 (suppl; abstr)
17. Long GV, Trefzer U, Davies MA, et al: Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol 13:1087-1095, 2012
18. Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAFmutated melanoma. N Engl J Med 367:107-114, 2012
19. Emery CM, Vijayendran KG, Zipser MC, et al: MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 106: 20411-20416, 2009
20. Wagle N, Emery C, Berger MF, et al: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-3096, 2011
21. Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-977, 2010
22. Poulikakos PI, Persaud Y, Janakiraman M, et al: RAF inhibitor resistance meditated by dimerization of aberrantly spliced BRAF(V600E). Nature 480: 387-390, 2012
23. Ascierto PA, Streicher HZ, Sznol M: Melanoma: A model for testing new agents in combination therapies. J Transl Med 8:38, 2010